drugset / Trial / NCT01011686
Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence
Summary
Fecal incontinence affects 18.4% adults in the community and greatly impacts quality of life. There's a problem like inconvenience, pain or allergic response in many therapeutic methods such as a surgical operation or material injection. ANT-SM is autologous adipose-derived stem cell, and so, expect of no immune responses. In this study, patients are given injection of ANT-AM in anal sphincter and followed for 4 weeks to test the safety.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “Few subject enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANT-SM | Cell therapy | — | Other |
Indications
No indication recorded.